Last Updated:
2:30 pm
Monday, June 23, 2025
Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. It operates through the Commercial Products, and Research and Development segments. The Commercial Products segment refers to the milestone and royalty revenue from license of intellectual property. The Research and Development segment focuses on the development of pharmaceutical products for the treatment of neurodevelopmental disorders. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
asx-neu
Market Cap
AU$1.76B
Volume
360657
Open
12.45
AU$
High
12.45
AU$
Low
11.88
AU$
Shares On Issue
131M
52 Week Low
8.61
AU$
52 Week High
22.44
AU$
Website
www.neurenpharma.com
Consensus
N/A
Last Report Date
N/A
Next Report Date
N/A
Next Dividend date
N/A
Short Sell
N/A
Short Sell Change (1mth)
N/A
Free ASX Market Outlook & Top Stock Picks for 2025
Instantly access our exclusive report and see which stocks our analysts are backing for growth this year.
Download Free Report
Related
No items found.
Our friendly team is here to help.
If you have any questions or feedback about our service, please feel free to contact us.
© Australian Stock Report Pty Ltd. All rights reserved